Pedersen T R
Circulation. 1983 Jun;67(6 Pt 2):I49-53.
In this study, 1884 patients who were selected from 3647 consecutive patients who survived at least 6 days after an acute myocardial infarction were randomized to double-blind treatment with either placebo or timolol and followed for 12-33 months. One hundred fifty-two patients in the placebo group and 98 in the timolol group died. The life-table cumulative probability of total death was 21.9% in the placebo group and 13.3% in the timolol group, corresponding to a relative reduction of 39.4% (p = 0.0003). One hundred thirty-one nonfatal reinfarctions were confirmed in the placebo group and 90 were confirmed in the timolol group, including events among withdrawn patients. The life-table probability rate of reinfarction was 16.4% in the placebo and 11.8% in the timolol group (p = 0.001). We conclude that chronic treatment with timolol in survivors of acute myocardial infarction who can tolerate beta-adrenergic blockade is effective in reducing both total mortality and reinfarction over 33 months.
在本研究中，从3647例急性心肌梗死后至少存活6天的连续患者中选取1884例患者，随机分为安慰剂组或噻吗洛尔双盲治疗组，并随访12 - 33个月。安慰剂组有152例患者死亡，噻吗洛尔组有98例患者死亡。安慰剂组全因死亡的生命表累积概率为21.9%，噻吗洛尔组为13.3%，相对降低了39.4%（p = 0.0003）。安慰剂组确诊131例非致命性再梗死，噻吗洛尔组确诊90例，包括退出研究患者中的事件。安慰剂组再梗死的生命表概率为16.4%，噻吗洛尔组为11.8%（p = 0.001）。我们得出结论，对于能够耐受β - 肾上腺素能阻滞剂的急性心肌梗死幸存者，噻吗洛尔长期治疗在33个月内有效降低全因死亡率和再梗死率。
